LaChapelle Robin 4
4 · ArriVent BioPharma, Inc. · Filed Feb 4, 2026
Research Summary
AI-generated summary of this filing
ArriVent (AVBP) COO Robin LaChapelle Receives 130,000-Share Award
What Happened
- Robin LaChapelle, Chief Operating Officer of ArriVent BioPharma, was granted a derivative award covering 130,000 shares on February 2, 2026. The reporting shows a $0.00 price (no cash paid at grant) and the award is reported as a derivative instrument (an option covering shares).
Key Details
- Transaction date: 2026-02-02; Filing date: 2026-02-04.
- Reported price: $0.00; Type: Award/Grant of a derivative (option) covering 130,000 shares.
- Vesting: 25% vests on February 2, 2027; remaining shares vest in 36 equal monthly installments thereafter, subject to continued service (per footnote).
- Shares owned after transaction: not specified in the provided filing details.
- Timeliness: Filing was submitted two days after the transaction; no late-filing indication in the record provided.
Context
- This was a compensation-related option grant, not an open-market purchase or sale. Such awards are common for executives and vest over time contingent on continued employment, so they reflect incentive alignment rather than an immediate market bet.
Insider Transaction Report
Form 4
LaChapelle Robin
Chief Operating Officer
Transactions
- Award
Stock Option (right to buy)
[F1]2026-02-02+130,000→ 130,000 totalExercise: $22.67Exp: 2036-02-02→ Common Stock (130,000 underlying)
Footnotes (1)
- [F1]The shares underlying this option vest as to 25% on February 2, 2027, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through the applicable vesting date.
Signature
/s/ James Kastenmayer, Attorney-in-Fact for Robin LaChapelle|2026-02-04